Roivant Is A Biopharmaceutical Company Founded In 2014Headquartered In Baselswitzerlandwith Roots In New Yorkthe Company Aims To Accelerate The Development And Commercialization Of Transformative Medicines Through Its Unique Decentralized Modelcreating Specialized Subsidiaries Known Asvants Each Vant Operates Independentlyfocusing On Specific Therapeutic Areas Or Health Technologieswhich Allows For Agile Drug Development And Commercialization Roivant Has Successfully Launched Vtamaa Tapinarof The First New Topical Treatment For Plaque Psoriasis In 25 Yearsand Has A Robust Pipeline Of Deprioritized Or Underdeveloped Drug Candidatesthe Company Has Achieved Significant Clinical Successparticularly In Dermatology And Immunologywith Ten Successful Phase 3 Trials Since 2019Roivant Also Has Subsidiaries Like Datavant And Altavant That Focus On Healthcare Data Optimization And Rare Diseasesrespectivelythe Company Emphasizes Diversity And Inclusion Within Its Leadership And Workforcetargeting Patients With Limited Treatment Options
